Under construction – not a live service
Sign in
Not yet taking people in ChinaNo phase

Comparing Two Operations for Thyroid Cancer Located in the Isthmus

Compares removing the isthmus alone with removing the whole thyroid in adults.

Plain-language title generated from the registry record
Registry title: Comparing the Therapeutic Efficacy of Extended Isthmusectomy Versus Total Thyroidectomy for Isthmus Tumors of the Thyroid

Key facts

Where
Hangzhou, ChinaSee the site

Where in China

  • 2nd Affiliated Hospital, School of Medicine, Zhejiang University, ChinaHangzhou, ChinaNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Second Affiliated Hospital, Zhejiang University, School of Medicine
Trial code
NCT07274605
Record updated
10 December 2025
Original description
Prospective randomized open phase III non-inferiority trial in cT1bN0N1aM0 isthmus tumors of the thyroid comparing: extended Isthmusectomy (Isthmusectomy + Central Neck Dissection)(experimental group) versus total thyroidectomy + Central Neck Dissection (reference group).Read full original descriptionShow less

Comparing the Therapeutic Efficacy of Extended Isthmusectomy Versus Total Thyroidectomy for Isthmus Tumors of the Thyroid: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial.

Prospective randomized open phase III non-inferiority trial in cT1bN0N1aM0 isthmus tumors of the thyroid comparing: extended Isthmusectomy (Isthmusectomy + Central Neck Dissection)(experimental group) versus total thyroidectomy + Central Neck Dissection (reference group).

Inclusion: Age 18 years or older; Diagnosis of low-risk differentiated thyroid cancer (papillary, follicular, or Hürthle cell carcinoma); Unifocal tumor located in the thyroid isthmus, cT1b; No evidence of extrathyroidal extension, assessed by preoperative ultrasound.

Exclusion: Aggressive pathological subtypes (e.g., tall cell, clear cell, columnar cell, or diffuse sclerosing variants of papillary thyroid carcinoma, as well as poorly differentiated types); cN1b; M1; Combined with other suspicious thyroid nodules within the lobes.

ClinicalTrials.gov NCT07274605